Signaling pathways in psoriasis pathogenesis in keratinocytes
Signaling pathways in psoriasis pathogenesis in keratinocytes. This diagram illustrates the intricate network of cytokine signaling pathways that are activated within keratinocytes by key proinflammatory cytokines such as IL-17A, IL-22, IFN-γ, and TNF-α, which are secreted by various immune cells. The complex interplay of cytokines, signaling cascades, and transcriptional regulators promotes the hyperproliferation, aberrant differentiation, and chronic inflammation observed in psoriatic keratinocytes. IFN-γ binding to its receptor activates the Janus kinase 1/2-signal transducer and activator of transcription 1 (JAK1/2-STAT1) signaling. Phosphorylated STAT1 induces the expression of C-X-C motif chemokine ligand 9 (CXCL9), CXCL10, and CXCL11. Similarly, TNF-α binding to the TNF receptor (TNFR) activates complex I, which comprises TNF receptor-associated death domain (TRADD), TNF receptor-associated factor 2 (TRAF2), receptor-interacting protein, and cellular inhibitor of apoptosis proteins (cIAPs). In turn, these activate the TGF-beta-activated kinase 1 (TAK1), mitogen-activated protein kinases (MAPKs), activator protein 1 (AP1), I-kappa-B kinase (IKK), inhibitor of kappa B (IκB), and nuclear factor-kappa B (NF-κB) pathways. The translocation of AP1 induces S100 calcium-binding protein A8 (S100A8), human beta-defensin 2 (hBD-2), hBD-3, and S100A7 expression, whereas NF-κB activation induces C-C motif chemokine ligand 20 (CCL20), keratin 17 (KRT17), prostaglandin-endoperoxide synthase 2 (PTGS2), vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), IL-8, intercellular adhesion molecule 1 (ICAM1), and vascular cell adhesion molecule 1 (VCAM1) expression. Additionally, IL-17A activates the MAPK, NF-κB, and STAT3 pathways by binding to the IL-17 receptor A/IL-17 receptor C (IL-17RA/IL-17RC) heterodimer. The IL-22 receptor 1/IL-10 receptor 2 (IL-22R1/IL-10R2) heterodimer activates STAT3 by phosphorylating tyrosine kinase 2 (TYK2) and JAK1 and inducing CCL20 and KRT17 expression. Additionally, IL-22 binding protein (IL-22BP) inhibits IL-22 activity by directly binding to it. Image created using BioRender.com (https://www.biorender.com (accessed on 13 March 2024)). Sharp arrows (→) indicate activation, and blunt arrows (⊣) indicate inhibition. Upward arrows (↱) indicate transcriptional activation